DelveInsight has launched a new report on BK virus Infection Market
BK virus (BKV) infection also known as polyomavirus is a member of the human polyomavirus family. BKV resides dormant in uroepithelial cells as it is mostly acquired in childhood and is not known to cause tissue damage in immunocompetent individuals. The virus can become reactivated in case of immunodeficiency (e.g., secondary to HIV infection or immunosuppressive medications), and result in cellular damage and organ dysfunction.
Request for free sample copy- https://www.delveinsight.com/sample-request/bk-virus-bkv-infection-market
BK virus Infection detailed Market size by therapies, covering the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017-2030
BK virus Infection Treatment
Other treatment alternatives can include use of ciprofloxacin, rapamycin or intravenous immunoglobulin. Intravenous immunoglobulin (IVIG) is a non-depleting agent, with antiviral and immunomodulatory properties.
Key player of the report
BK virus Infection Market Insights
BK polyomavirus causes frequent infections during childhood and establishes persistent infections within renal tubular cells and the uroepithelium, with minimal clinical implications. BK polyomavirus (BKV) is a member of the Polyomaviridae family of double-stranded DNA (dsDNA) viruses. However, the reactivation of the infection of BKV in immunocompromised individuals following renal or hematopoietic stem cell transplantation may cause serious complications, including BKV-associated nephropathy (BKVAN), ureteric stenosis, or hemorrhagic cystitis.
BK virus Infection Market Size
The dynamics of BK virus (BKV) Infection market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world. The launch of emerging therapies is expected during the forecast period of 2020–2030.
Owing to the positive outcomes of the some of the rare candidates during the developmental stage by key players, such as SL VAXiGEN (SL-V10), and others companies that are under preclinical phase of development have the potential to create a significant positive shift in BK virus infection in the market size.
BK virus Infection Market Report Highlights
Table of content
1. Key Insights
2. Executive Summary of BK virus (BKV) Infection
3. Competitive Intelligence Analysis for BK virus (BKV) Infection
4. BK virus (BKV) Infection: Market Overview at a Glance
5. BK virus (BKV) Infection: Disease Background and Overview
6. Patient Journey
7. BK virus (BKV) Infection Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of BK virus (BKV) Infection Treatment
11. Marketed Products
12. Emerging Therapies
13. BK virus (BKV) Infection: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
16. Access and Reimbursement Overview of BK virus (BKV) Infection
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
Related reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/